Sanofi (SNY) and Regeneron (REGN) to Lower Net Price of Praluent; Praluent will become Exclusive PCSK9 inhibitor Therapy on Express Scripts (ESRX) National Formulary
Tweet Send to a Friend
Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced they will lower the net price of Praluent® (alirocumab) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
